ARKG

ARK Genomic Revolution ETF, ticker ARKG, is an exchange-traded fund managed by ARK Investment Management LLC. It seeks long-term capital appreciation by investing in companies that enable the genomic revolution, including gene editing, sequencing, diagnostics, bioinformatics, and related life sciences services. The fund aims to identify disruptive innovations and allocate capital to firms expected to benefit from breakthroughs in genomics.

Investment approach and holdings: ARKG employs an active, research-driven strategy with a high-conviction, growth-oriented portfolio. It tends to be more concentrated than broad-market funds, focusing on a relatively small number of holdings that ARK researchers view as having the strongest upside from genomic advances. The fund's holdings span primarily U.S.-listed equities, with some international exposure, across biotechnology, pharmaceutical, sequencing, and related technology sectors.

Performance and risk: As with many biotechnology-focused investments, ARKG can be volatile and sensitive to regulatory developments, clinical trial results, drug approvals, and shifts in investor appetite for disruptive healthcare innovation. Investors face concentration risk due to the fund’s focused mandate, sector risk tied to biotechnology and genomics, and liquidity risk for smaller or less liquid holdings.

Background: ARK Genomic Revolution ETF is part of ARK Investment Management’s family of thematic ETFs focused on disruptive innovation. The fund’s holdings are periodically reviewed and rebalanced to reflect ongoing research and evolving expectations about genomic technology and its commercialization.